Company intelligence / Profile preview

Bio-K+

Ownership: Private
Employees: ~200
Development stage: Commercial

Overview

Over three decades of research and clinical trials have validated the efficacy of the unique Bio-K+ probiotic formula. The company’s products are used in over 200 hospitals across North America for preventing AAD and CDI. Their probiotics were the first approved by Health Canada to help prevent C. difficile-associated diarrhea.[4][6] Clinical results show measurable benefits in gut health and infection prevention.

Therapeutic areas: GastroenterologyImmunologyInfectious Diseases
Modalities: Probiotics (live bacterial strains)
Industry: Biotech

Drug pipeline

2 assets

lactobacillus acidophilus CL1285

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

No major pharma partnerships publicly listed; trusted by healthcare professionals/hospitals.[4]

Beyond the preview

Go deeper on Bio-K+.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bio-K+.

Explore the full profile